TIAA CREF Investment Management’s Harvard Bioscience HBIO Stock Holding History

TIAA CREF Investment Management’s Portfolio HBIO Stock Details HBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	$275K	Sell	6,387 -140	-2%	-$5.08K	﹤0.01%	2805
2018 Q4	$208K	Hold	6,527	–	–	﹤0.01%	2867
2018 Q3	$343K	Sell	6,527 -319	-5%	-$17.9K	﹤0.01%	2850
2018 Q2	$366K	Buy	+6,846	New	+$351K	﹤0.01%	2898
2016 Q2	–	Sell	-11,453	Closed	-$346K	–	3169
2016 Q1	$346K	Hold	11,453	–	–	﹤0.01%	2886
2015 Q4	$397K	Hold	11,453	–	–	﹤0.01%	2955
2015 Q3	$433K	Hold	11,453	–	–	﹤0.01%	2925
2015 Q2	$653K	Buy	+11,453	New	+$652K	﹤0.01%	2885
2014 Q2	–	Sell	-11,739	Closed	-$556K	–	3140
2014 Q1	$556K	Hold	11,739	–	–	﹤0.01%	2910
2013 Q4	$552K	Sell	11,739 -3,745	-24%	-$164K	﹤0.01%	2930
2013 Q3	$617K	Sell	15,484 -180	-1%	-$7.08K	﹤0.01%	2878
2013 Q2	$562K	Buy	+15,664	New	+$600K	﹤0.01%	2899

Other funds holding HBIO

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

TIAA CREF Investment Management's HBIO Position: Q1 2019 in Review

TIAA CREF Investment Management reduced its Harvard Bioscience (HBIO) stake by 2.1% in Q1 2019, selling an estimated $5.08K and leaving 6,387 shares worth $275K. The position accounts for ﹤0.01% of the portfolio, ranked #2805.

TIAA CREF Investment Management first reported a position in HBIO in Q2 2013 and has held it in 12 quarters since. The position peaked at $653K in Q2 2015. 87 funds tracked by Wall St. Rank hold HBIO as of Q1 2019.

TIAA CREF Investment Management held 6,387 shares of Harvard Bioscience worth $275K as of Q1 2019.
TIAA CREF Investment Management sold 140 Harvard Bioscience shares in Q1 2019, an estimated $5.08K.
Harvard Bioscience made up ﹤0.01% of TIAA CREF Investment Management's portfolio in Q1 2019, its #2805 holding.
TIAA CREF Investment Management first reported a position in Harvard Bioscience in Q2 2013 and has held it in 12 quarters since.
TIAA CREF Investment Management's Harvard Bioscience position peaked at $653K in Q2 2015.
87 funds tracked by Wall St. Rank held Harvard Bioscience as of Q1 2019.

Based on TIAA CREF Investment Management's 13F filing for Q1 2019, filed 14 May 2019.